Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Chemotherapy-induced cardiotoxicity and mitigation

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 2,239 works 42 author topics

Works

2,239 works

  1. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity 2023
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 1% OpenAlex 100.0%

    Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX's action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen sp…

  2. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.4%

    No abstract yet.

  3. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.4%

    No abstract yet.

  4. Protective Effects of Carvedilol Against Anthracycline Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.4%

    No abstract yet.

  5. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy 2006
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.4%

    No abstract yet.

  6. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) 2022
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    SCOPUS: ar.j

  7. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex top 10% OpenAlex 98.8%

    No abstract yet.

  8. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex top 10% OpenAlex 98.8%

    No abstract yet.

  9. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex top 10% OpenAlex 98.8%

    No abstract yet.

  10. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study 2013
    YÖKSİS SJR Q2 JCR Q1 OpenAlex top 10% OpenAlex 98.8%

    No abstract yet.

  11. TAXUS III Trial 2003
    SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR). METHODS AND RESULTS: The TAXUS III trial was a single-arm, 2…

  12. Protective effect of lycopene on adriamycin induced cardiotoxicity and nephrotoxicity 2006
    YÖKSİS OpenAlex top 10% OpenAlex 93.0%

    No abstract yet.

Academicians

42 academicians